DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

ZTS·Zoetis Inc.

$.
+. (+.%)
High
$77.38
Open
$75.42
Market Cap
32.26B
52W High
$160.48
Low
$74.55
P. Close
$74.53
P/E
12.20
52W Low
$71.47
Fwd P/E
10.08
DailyIQ Est.
$119.10
Technical Score (1D)
50
NEUTRAL
News Sentiment
51
MIXED
Zoetis has just launched Lenivia® (izenivetmab injection) in Canada and the EU, a long‑acting monoclonal antibody that delivers up to three months of osteoarthritis pain relief with a single subcutaneous dose. The launch follows a nine‑month European field study that demonstrated sustained pain reduction and benefits observable as early as day 7, giving the product a strong clinical credibility base. By entering the canine OA market, which affects up to 40 % of dogs, Zoetis expands its chronic disease portfolio and positions itself to capture a growing share of a high‑margin therapeutic niche. The new product could shift prescribing habits away from NSAIDs and other short‑acting biologics, potentially boosting Zoetis’s veterinary therapeutics revenue over the next 1–10 trading days. Market acceptance will hinge on pricing, reimbursement, and competition from existing anti‑NGF therapies, so early sales data will be a key indicator of the launch’s success. Investors should watch for the first‑quarter sales figures and any early post‑marketing safety signals that could influence the product’s uptake. Regulatory approvals in additional markets, such as the United States, could further accelerate revenue growth and broaden the product’s reach. The launch also signals Zoetis’s continued focus on biologics, which may attract additional capital allocation toward research and development in this area. In the short term, analysts should monitor the company’s earnings releases for any mention of Lenivia’s contribution and any guidance updates that reflect the product’s market performance.
Earnings Summary
Zoetis Inc. is a global leader in animal health, offering a broad portfolio of medicines, vaccines, diagnostics, and services for livestock and companion animals, positioning it within the specialty drug manufacturing sector. In the most recent reporting cycle, the company posted earnings per share of $1.53 in Q1 2026, slightly below the $1.615 estimate, while revenue fell to $2.262 billion from $2.387 billion in Q4 2025; this contrasts with the prior two quarters (Q3 2025 and Q2 2025) where EPS rose to $1.76 and $1.70 and revenue peaked at $2.460 billion and $2.400 billion, respectively, indicating a modest acceleration in profitability but a deceleration in top‑line growth. Historically, Zoetis has delivered earnings that beat consensus in three of the last four quarters—Q4 2024, Q2 2025, and Q3 2025—while revenue growth has remained relatively flat, underscoring a pattern of solid profitability amid modest sales expansion. Recent developments include the launch of Lenivia® in Canada and the EU, a long‑acting monoclonal antibody for canine osteoarthritis that could shift prescribing habits away from NSAIDs and add a high‑margin therapeutic niche; the company also announced the acquisition of VitalRADS, a veterinary teleradiology platform, which is expected to accelerate diagnostic turnaround times and open new revenue streams. Investors should watch for the first‑quarter sales figures of Lenivia, the integration progress of VitalRADS, and any guidance revisions that reflect the impact of these initiatives, as these factors will likely shape the company’s near‑term earnings trajectory. This pattern suggests a cautious but resilient growth outlook.

EPS

EstBeatMiss
$1.33$1.48$1.63$1.77$1.92Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.85 - -
Q1'26$1.62$1.53-5.3%
Q4'25$1.62$1.48-8.4%
Q3'25$1.62$1.70+4.8%
Q2'25$1.61$1.76+9.2%
Q1'25$1.40$1.48+5.8%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.5B$2.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.5B - -
Q1'26$2.3B$2.3B-2.8%
Q4'25$2.3B$2.4B+3.1%
Q3'25 - $2.4B -
Q2'25 - $2.5B -
Q1'25 - $2.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ZTS Stock Snapshot

ZTS is currently trading at $77.28, giving Zoetis Inc. a market cap of 32.26B and a P/E ratio of 12.2. Today's range spans $74.55–$77.38, with shares opening at $75.42 and moving up $2.75 (3.7%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 51/100.

Over the past year ZTS has traded between $71.47 and $160.48 - the current price is +8.1% off the 52-week low and -51.8% from the high. 26 analysts cover the stock with a Hold consensus and a mean 12-month target of $114.76 (range $80.00–$160.00), implying upside of +48.5%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, ZTS (50/100, HOLD, price $77.28, near 52-week lows) is waiting for that resolution. Sentiment: neutral at 51/100. The current P/E ratio stands at 12.2. With 32.26B in market cap, the 52-week range of $71.47–$160.48 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

Portfolio construction in Healthcare often uses large-cap names like ZTS as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 50/100 (HOLD) at $77.28 (near 52-week lows) and neutral sentiment (51/100) frame the position as a catalyst play within the $71.47–$160.48 annual range rather than a directional bet.